Acute Myeloid Leukemia
SU11248 produces short-term partial remissions in leukemia patients
Published in Blood Weekly, March 31st, 2005
According to a study from Germany, "fifteen patients with refractory acute myeloid leukemia (AML) were treated in a phase 1 study with SU11248, an oral kinase inhibitor of fms-like tyrosine kinase 3 (Flt3), Kit, vascular endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF) receptors."
"Separate cohorts of patients received SU11248 for 4-week cycles followed by either a 2- or a 1 -week rest period. At the starting dose level of 50 mg (n=13), no dose-limiting toxicities were observed. The most frequent grade 2 toxicities were edema, fatigue, and oral...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2005-03-31)
More Articles from Blood Weekly
- Blood Banking
Quality control programs ensures quantity/quality of preserved cord blood - Embryonic Stem Cell Research
Frozen-thawed embryos superior to fresh for embryonic stem cell establishment - Tissue Engineering
Surgisis collagen mesh useful alternative for tissue replacement in pediatrics - Tissue Engineering
Synchronous contractions induced in cardiac tissue engineered constructs - Umbilical Cord Blood
Cord blood banking regulated in the EU to assure safety/efficacy - Anemia
Fanconi anemia protein studied, regulated interaction with chromatin revealed - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
